Tcg Advisory Services, LLC Genprex, Inc. Transaction History

Tcg Advisory Services, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 06, 2024	BUY	$0.19 - $0.37 $237 - $462	1,250 Added 3.88%	33,500 $7,000
Q3 2023 Nov 14, 2023	BUY	$0.37 - $1.04 $3,459 - $9,724	9,350 Added 40.83%	32,250 $12,000
Q2 2023 Aug 14, 2023	BUY	$0.74 - $1.1 $666 - $990	900 Added 4.09%	22,900 $21,000
Q1 2023 Apr 24, 2023	BUY	$0.76 - $1.78 $760 - $1,780	1,000 Added 4.76%	22,000 $20,000
Q4 2022 Feb 10, 2023	BUY	$1.0 - $58.8 $1,000 - $58,800	1,000 Added 5.0%	21,000 $30,000
Q3 2022 Nov 14, 2022	BUY	$1.32 - $58.0 $3,960 - $174,000	3,000 Added 17.65%	20,000 $28,000
Q2 2022 Aug 12, 2022	BUY	$1.28 - $2.31 $1,280 - $2,310	1,000 Added 6.25%	17,000 $24,000
Q1 2022 May 13, 2022	BUY	$1.82 - $3.5 $29,120 - $56,000	16,000 New	16,000 $36,000

600

Ticker GNPX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,020,300
Market Cap $76.8M
Description
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incor...

Get notified when there are updates to the investment portfolio of Tcg Advisory Services, LLC, based on Form 13F filings with the SEC.

Stay updated on Tcg Advisory Services, LLC with notifications on news.